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Fetal events and obstetric complications are associated with schizophrenia. Here we report the results of a family-
based candidate-gene study that assesses the role of maternal-fetal genotype incompatibility at the RHD locus in
schizophrenia. We adapted the case-parent–trio log-linear modeling approach to test for RHD maternal-fetal ge-
notype incompatibility and to distinguish this effect from a high-risk allele at or near the RHD locus and from a
direct maternal effect alone. Eighty-eight patient-parent trios, 72 patient-mother pairs, and 21 patient-father pairs
were genotyped at the RHD locus. Of the 181 patients, 62% were male and 81% were second born or later. Only
three patients were born after prophylaxis against maternal isoimmunization had become common practice. There
was significant evidence for an RHD maternal-fetal genotype incompatibility, and the incompatibility parameter
was estimated at 2.6. There was no evidence to support linkage/association with schizophrenia at or near the RHD
locus nor any evidence to support the role of maternal genotype effect alone. Our results replicate previous findings
that implicate the RHD locus in schizophrenia, and the candidate-gene design of this study allows the elimination
of alternative explanations for the role of this locus in disease. Thus, the present study provides increasing evidence
that the RHD locus increases schizophrenia risk through a maternal-fetal genotype incompatibility mechanism
that increases risk of an adverse prenatal environment (e.g., Rh incompatibility) rather than through linkage/
association with the disorder, linkage disequilibrium with an unknown nearby susceptibility locus, or a direct
maternal effect alone. This is the first candidate-gene study to explicitly test for and provide evidence of a maternal-
fetal genotype incompatibility mechanism in schizophrenia.
Introduction
Schizophrenia is a neuropsychiatric disorder that occurs
in .5%–1% of the population worldwide. It is charac-
terized by a constellation of features, including delu-
sions, hallucinations, disorganized speech and behavior,
flattened affect, and inability to initiate and persist in
goal-directed activities (American Psychiatric Associa-
tion 1994). It is a debilitating chronic disorder with age
at onset typically between the late teens and mid-30s
(American Psychiatric Association 1994).
There is compelling evidence that both genetic and
environmental factors are involved in the etiology of
schizophrenia. Furthermore, there is growing evidence
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that the environmental risk factors for schizophrenia
include processes involving the prenatal environment
(Cannon 1997; Geddes et al. 1999; Cannon et al. 2000;
Cantor-Graae et al. 2000; Hulshoff et al. 2000; Lewis
and Lieberman 2000; Cannon et al. 2002). Unfortu-
nately, the causes for prenatal complications are quite
heterogeneous and difficult to document reliably, mak-
ing it difficult to test the role of prenatal environmental
insults in the pathogenesis of schizophrenia. Further-
more, although some prenatal environmental insults
may have a genetic basis, the mechanism by which the
genes act may not appear to follow Mendelian inheri-
tance patterns, creating problems in the identification
of susceptibility loci when traditional genetic analyses
are used.
Rh incompatibility, a phenotype that exhibits non-
Mendelian inheritance, has been implicated as a risk
factor for schizophrenia in several studies employing
different designs and samples (Hollister et al. 1996;
Cannon et al. 2002). Three population studies that in-
vestigated the association between Rh incompatibility
and schizophrenia were included in a recent meta-anal-
ysis (Cannon et al. 2002), yielding an overall significant
effect and an estimated overall odds ratio of 2.0. Ad-
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ditional confirmation is provided by a case-control
study conducted in a large Danish sample of individuals
born between 1959 and 1961 (Hollister et al. 1996). In
that study, the proportion of Rh-incompatible male off-
spring (2.1%) was significantly larger than the propor-
tion of schizophrenics in a cohort of Rh-compatible
male offspring (0.8%), yielding a relative risk of 2.78.
In addition, in a review of previous research on Rh
hemolytic disease of the newborn (HDN) and schizo-
phrenia (Hollister and Kohler 2001) the results of a
recent Finnish study (unpublished as yet) are summa-
rized in which the rate of schizophrenia was significantly
higher among individuals who survived Rh HDN than
among individuals who were not exposed to this ob-
stetric complication (odds ratio 2.0). In all of these stud-
ies, Rh phenotype information (Rh positive and Rh neg-
ative) from labor, delivery, and birth records formed the
basis of analysis. When phenotype information and
these study designs are used, however, it is not possible
to clarify whether the effect of the RHD locus (MIM
111680) results from a maternal-fetal genotype incom-
patibility, as we hypothesize; from linkage and associ-
ation (LD) with a high-risk susceptibility allele at or
near the RHD locus; or from the effects of the maternal
genotype acting alone.
Rh incompatibility is the result of a maternal-fetal
genotype incompatibility at the RHD locus, in which
the mother is Rh negative (d/d) and the fetus is Rh
positive (D/d). One reason that Rh incompatibility may
be harmful to the fetus is that it may lead to hypoxia,
an obstetric complication found to be associated with
schizophrenia (Cannon et al. 1993, 2000; Cannon
1997; Zornberg et al. 2000; Dalman et al. 2001). Rh
incompatibility also can lead to an increase in uncon-
jugated bilirubin, a neurotoxin (Hansen 2000, 2001) to
which undifferentiated glial cells are sensitive (Amit and
Brenner 1993; Rhine et al. 1999). Glial cell abnormal-
ities also have been associated with schizophrenia (Cot-
ter et al. 2001; Moises et al. 2002). Thus, one biological
mechanism that can create an adverse prenatal envi-
ronment is caused by a maternal-fetal genotype com-
bination that adversely affects the developing fetus by
inducing a maternal immunological attack, which then
increases susceptibility to schizophrenia. This mecha-
nism, which we refer to as a “maternal-fetal genotype
incompatibility,” is consistent with the teratogenic an-
tibody hypothesis of disease, which posits that a preg-
nant female can develop antibodies in response to some
antibody-producing stimulus (e.g., contact with pater-
nal antigens) that can interfere with normal fetal neu-
rodevelopment and increase susceptibility to disease,
such as schizophrenia (Laing et al. 1995). Of particular
importance is the fact that maternal-fetal genotype in-
compatibilities that initiate adverse prenatal events (at
RHD or at other relevant loci), have the potential to
be detected in genetic analyses of existing data sets, even
years after the adverse event has occurred.
We report the results of a family-based candidate-gene
study that assesses the role of maternal-fetal genotype
incompatibility at the RHD locus in schizophrenia. We
adapted the case-parent–trio log-linear modeling ap-
proach (Weinberg et al. 1998; Wilcox et al. 1998) to
develop a maternal-fetal genotype incompatibility (MFG)
test (Sinsheimer et al., in press), which is sensitive to the
effects of RHD maternal-fetal genotype incompatibility
and can distinguish these effects from a high-risk allele
at or near the RHD locus in the affected child’s genotype
or the maternal genotype.
Material and Methods
Subjects
Subjects were ascertained from a larger well-described
and characterized Finnish schizophrenia sample (Hovatta
et al. 1999; Ekelund et al. 2000, 2001; Paunio et al. 2001).
Probands in the larger sample were identified through
nationwide health and population registers. First-degree
relatives subsequently were invited to participate through
permission given by the proband. The research was ap-
proved by the Ministry of Social Affairs and Health (Fin-
land) and the appropriate institutional review boards, and
informed consent was obtained from subjects. DSM-IV
(American Psychiatric Association 1994) best-estimate
lifetime diagnoses were made independently by two psy-
chiatrists or psychiatric residents from all available in-
patient and outpatient records for probands and their
relatives. For the current study, we selected the youngest
individual in each independent nuclear family with a di-
agnosis of schizophrenia, schizoaffective psychosis dis-
order, or schizophrenia spectrum disorder (i.e., paranoid
personality, schizoid personality, and schizotypy) and at
least one parent available for genotyping. This selection
strategy was used to maximize the likelihood of detecting
an RHD maternal-fetal genotype incompatibility effect,
since second-born or later babies are more likely to be at
risk for the immunological sequelae of RHD maternal-
fetal genotype incompatibility (Guyton 1981).
The study sample of 450 Finnish individuals was com-
posed of 88 patient-parent trios, 72 patient-mother pairs,
and 21 patient-father pairs. Of the 181 patients, 112 were
male (62%), 147 were second born or later (81%), 145
had received a diagnosis of schizophrenia (80%), 25 had
received a diagnosis of schizoaffective psychosis disorder
(14%), and 11 had received a schizophrenia spectrum
diagnosis (6%). Approximately 12% of mothers and 6%
of fathers fell into one of those three diagnostic categories.
Patients were born during the period 1937–1973, with a
median birth year of 1957. Prophylaxis against maternal
isoimmunization was not available for the vast majority
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Table 1
Description of Trio Categories, Expected Values, and
Distribution of Data Under the Model with RHD Maternal-Fetal
Genotype Incompatibility and LD
CELL
NUMBER
GENOTYPE
EXPECTED
VALUEa NbMaternal Paternal
Affected
Child
1 D/D D/D D/D R2g1 44.3
2 D/D D/d D/D R2g2 16.0
3 D/D D/d D/d R1g2 16.7
4 D/d D/D D/D R2g2 15.6
5 D/d D/D D/d R1g2 16.8
6 D/D d/d D/d R1g3 3.2
7 d/d D/D D/d MR1g3 7.8
8 D/d D/d D/D R2g4 13.0
9 D/d D/d D/d 2R1g4 15.4
10 D/d D/d d/d g4 12.1
11 D/d d/d D/d R1g5 2.7
12 D/d d/d d/d g5 3.7
13 d/d D/d D/d MR1g5 6.4
14 d/d D/d d/d g5 2.4
15 d/d d/d d/d g6 4.8
NOTE.—Trio categories at risk for incompatibility and their
counterpart compatible trio categories are underlined.
a M is the relative risk to a child due to a maternal-fetal genotype
incompatibility at the RHD locus, R1 and R2 are the relative risk
of disease to a child carrying one and two d alleles, respectively,
and gj ( ) are the mating-type parameters.jp 1, … ,6
b Number of trios based on the final iteration of the expectation
step from the EM algorithm (Weinberg 1999), using data on 88
patient-parent trios, 72 patient-mother pairs, and 21 patient-father
pairs.
of the patients in the study, since only three patients were
born after it had become common practice in Finland—
that is, after 1969 (Eklund and Nevanlinna 1986). Of the
181 patients, 12 had the genotype D/d (Rh positive) when
the maternal genotype was d/d (Rh negative) and were at
risk for the sequelae of RHD maternal-fetal genotype in-
compatibility. An additional nine D/d patients who were
missing maternal genotypes also were potentially at risk
for sequelae of RHD maternal-fetal genotype incompat-
ibility. The number of older heterozygous siblings of these
21 patients ranged from 0 to 5. There was at least one
older sibling with the D/d genotype for 11 of the 12
known at-risk patients and 3 of the 9 potential at-risk
patients, thereby increasing the chance that maternal
isoimmunization had occurred prior to the pregnancy
with these at-risk patients.
Genotyping Methods
DNA was extracted from EDTA blood, according to
a standard procedure (Blin and Stafford 1976). A PCR-
RFLP was used to detect the RHD genotype (Wagner
and Flegel 2000). This method identifies all three ge-
notypes (D/D, D/d, and d/d). PCR was performed using
primers rez7 (5′-CCTGTCCCCATGATTCAGTTACC-
3′) and rnb1 (5′-CCTTTTTTTGTTTGTTTTTGGCGG-
TGC-3′) and the expand high-fidelity PCR system (Dy-
NAzyme EXT DNA Polymerase). Annealing was at
65C and extension was for 3 min at 72C. PCR prod-
ucts were digested with PstI for 3 h at 37C, and frag-
ments were visualized using a 1.5% agarose gel. Ge-
notyping was conducted blind to diagnostic status.
Genotype data were checked for errors through use of
PEDCHECK (O’Connell and Weeks 1998) and MEN-
DEL 4.0 (Douglas et al. 2000; Lange 2002; Sobel et al.
2002). Of the 269 genotyped parents, 10.4% were d/d,
44.2% were D/d, and 45.3% were D/D. Thus, the fre-
quency of the D allele was .67 and the frequency of the
d allele was .33.
Four microsatellite markers flanking the RHD locus
(D1S368 [17.1 cM from RHD], D1S552 [6.9 cM from
RHD], D1S1622 [5.1 cM from RHD], and D1S513 [8.5
cM from RHD]) were obtained and genotyped as de-
scribed elsewhere (Ekelund et al. 2001).
Statistical Analyses
Tests of (i) RHD maternal-fetal genotype incompati-
bility, (ii) a high-risk allele at or near the RHD locus in
the affected child’s genotype, or (iii) a high-risk allele at
or near the RHD locus in the maternal genotype were
performed using the MFG test (Sinsheimer et al., in
press), an adaptation of the log-linear model for case-
parent trios (Weinberg et al. 1998; Wilcox et al. 1998;
Umbach and Weinberg 2000). The direct effect of the
affected child’s genotype (or maternal genotype) and the
effect of maternal-fetal genotype incompatibility are
modeled jointly in the MFG test, to remove potential
confounding of these effects. The joint model is essential
to rule out the existence of any susceptibility loci of
minor effects that may be in LD with a putative incom-
patibility locus or to rule out the effect of maternal ge-
notype alone on the fetal environment.
Because the RHD locus is biallelic, each genotyped
patient-parent trio falls into one of 15 possible categories
(see table 1). As in the study by Weinberg et al. (1998),
we assume that mating-type frequencies are symmetric;
thus, the 15 trio combinations in table 1 correspond to
six different mating types. No assumption of Hardy-
Weinberg equilibrium is made. Under a model where
disease risk is increased under maternal-fetal genotype
incompatibility or because of a high-risk allele at or near
the RHD locus in the affected child’s genotype, the ex-
pected frequencies of the genotyped trio categories de-
pend on the mating type parameters, gj ( ),jp 1, … ,6
the relative risk of disease to a child carrying two d
alleles, R2; the relative risk of disease to a child carrying
one d allele, R1; and the relative risk of disease to a child
due to a maternal-fetal genotype incompatibility at the
RHD locus, M (see table 1). If there is an incompatibility
effect, one would expect to see a greater number of in-
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compatible patient-parent trios than their counterpart
compatible trios within a mating type. For hypotheses
about the RHD maternal-fetal genotype incompatibility
parameter, the number in cell 7 should be greater than
that in cell 6, and the number in cell 13 should be greater
than that in cell 11 (see table 1).
Under this scenario and under the assumption of Pois-
son-distributed counts, the natural logarithm of the
expected number in the ith trio combination (ip
) can be summarized as1, … ,15
( ) ( ) ( )ln m p ln g ln M Ii j {Motherpd/d,ChildpD/d}i i
( ) ( ) ln R ln 2 I ,ic {MotherpFatherpChildpD/d}i i i
where Ric denotes the relative risk of schizophrenia given
that the child in combination i has , 1, or 2 copiescp 0
of the d allele (where ), and I is the indicatorR p 10
function. When associated with , the indicator var-ln (M)
iable takes on a value of 1 for the maternal-fetal ge-
notype combination in which the mother is d/d (Rh neg-
ative) and the child is D/d (Rh positive), and a value of
0 otherwise. When associated with the constant ,ln (2)
the indicator variable takes on a value of 1 when mother,
father, and child are all heterozygous, and a value of 0
otherwise.
Under a model in which disease risk is increased under
maternal-fetal genotype incompatibility or because of a
high-risk allele at or near the RHD locus in the maternal
genotype, the expected frequencies of the trio categories
depend on these same mating type parameters, gj (jp
); the relative risk of disease to a child whose1, … ,6
mother has two d alleles, S2; the relative risk of disease
to a child whose mother has one d allele, S1; and the
relative risk of disease, to a child, that is due to a maternal-
fetal genotype incompatibility at the RHD locus, M.
Under this scenario, the natural logarithm of the
expected number in the ith trio combination (ip
) can be summarized as1, … ,15
( ) ( ) ( )ln m p ln g ln M Ii j {Motherpd/d,ChildpD/d}i i
( ) ( ) ln S ln 2 Iic {MotherpFatherpChildpD/d}i i i
In this case, Sic denotes the relative risk of schizophrenia
to the child, given that the mother in combination i has
, 1, or 2 copies of the d allele (where ).cp 0 S p 10
To use patient-mother and patient-father pairs, the
observed log likelihood must incorporate incomplete
data—for example, trios missing one parental genotype.
The observed log likelihood is analogous to the one pre-
sented by Weinberg (1999). A test of the parameter(s)
of interest is performed by computing a likelihood-ratio
test statistic (LRT) from the log likelihoods obtained by
maximizing the fit of the data under specified null and
alternative models. The observed data log likelihood can
be maximized directly through use of a recursive quad-
ratic programming routine (Lange 1991) or an expec-
tation-maximization (EM) algorithm (Weinberg 1999).
Both approaches treat the partial information from in-
completely genotyped trios in an unbiased manner and
yield the same parameter estimates and observed data
log-likelihood maxima. In addition to obtaining param-
eter estimates from the EM algorithm, we also calculated
the number of patient-parent trios that are expected to
fall into each of the 15 categories from the final expec-
tation step. We calculated the asymptotic SEs for the
parameters through use of the information matrix ob-
tained from the direct maximization of the observed data
log likelihood. The LRT is asymptotically distributed as
x2. When we test for the incompatibility effect in the
possible presence of LD, the LRT has 1 df. When we
test for LD effects in the possible presence of an incom-
patibility effect (or for maternal effects in the possible
presence of an incompatibility effect), the LRT has 2 df.
Analyses based on the MFG test were performed using
MISMATCH (Sinsheimer 2002).
Tests of linkage and association at flanking microsat-
ellite markers were performed using an extension of the
transmission/disequilibrium test (TDT) (Lazzeroni and
Lange 1998) in MENDEL 4.0 (Lange 2002). These anal-
yses included 155 affected siblings of the 181 patients.
Results
We tested the primary hypothesis of an RHD maternal-
fetal genotype incompatibility effect in the possible pres-
ence of LD by comparing the unconstrained model in
which and the two LD parameters, andln (M) ln (R )1
, are estimated, to a constrained model in whichln (R )2
and are estimated but is constrainedln (R ) ln (R ) ln (M)1 2
to its null value (0). This comparison produced signifi-
cant evidence for an RHD maternal-fetal genotype in-
compatibility ( ; 1 df; [one-sided] ).2x p 3.72 Pp .027
In this analysis, a one-sided test is used, because we are
replicating a number of previous findings that suggest
that an RHD maternal-fetal genotype incompatibility
increases risk to the developing fetus and it is biologically
implausible that RHD maternal-fetal genotype incom-
patibility would decrease the risk of schizophrenia.
Estimates of the three parameters of the uncon-
strained model were obtained by maximizing the log
likelihood. Table 1 provides the number of patient-par-
ent trios falling into the 15 categories on which these
estimates are based. There are fractional numbers be-
cause patient-mother–only and patient-father–only data
are probabilistically apportioned across several trio cat-
egories in an unbiased manner. The estimate of ln (M)
is 0.96 ( ; 90% CI 0.12–1.80), is0.13SEp 0.51 ln (R )1
( ; 90% CI 0.34–0.08), and is 0.22SEp 0.13 ln (R )2
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( ; 90% CI 0.39–0.83). For ease of inter-SEp 0.37
pretation, we can consider M, R1, and R2, which have
values of 2.6, 0.87, and 1.25, respectively, rather than
, , and . Looking at table 1, it is ap-ln (M) ln (R ) ln (R )1 2
parent that the number of trios falling into the RHD
maternal-fetal genotype incompatible categories (cells 7
and 13) is larger than the number of trios falling into
their compatible counterparts (cells 6 and 11). Fur-
thermore, the maximum-likelihood estimate of M can
be understood intuitively by forming the ratio of the
sum of the two incompatible categories to the sum of
their compatible counterparts; this produces a value of
2.4, which is consistent with the maximum-likelihood
estimate.
To rule out the presence of a high-risk allele at or
near the RHD locus in the affected child’s genotype, we
then conducted two different analyses. First, we used
the log-linear case-parent–trio model and compared the
unconstrained three-parameter model ( , ,ln [M] ln [R ]1
) to a model in which is estimated andln [R ] ln (M)2
and are constrained to 0 (null value).ln (R ) ln (R )1 2
There was no evidence to support linkage/association
with schizophrenia at or near the RHD locus ( 2x p
; 2 df; [two-sided] ). Because there is no bi-1.1 Pp .58
ological justification for specifying the direction of an
effect for the linkage/association parameters under the
alternative hypothesis, a two-sided level of significance
is used in this analysis.
Next, we tested for linkage or association between
schizophrenia and the RHD locus, as well as several
markers near the RHD locus (D1S368, D1S552, RHD,
D1S1622, and D1S513), using an extension of the TDT.
There was no evidence for linkage or association with
schizophrenia at any of these loci (all P values 1.05). This
is consistent with results of similar analyses performed
in the entire Finnish sample (221 families, 557 affected
individuals) at the four flanking microsatellite markers,
which also were not significant (Ekelund et al. 2001 [and
their online supplementary material]). Using formulas de-
scribed by Knapp (1999), we determined that the current
study sample size had 10.93 power to detect linkage at
the RHD locus with under dominant, recessive,l p 1.2s
additive, and multiplicative models. Together, these anal-
yses provide further evidence that the effect demonstrated
at the RHD locus represents the result of a maternal-
fetal genotype incompatibility, rather than the direct ef-
fect of a high-risk allele at or near the RHD locus in the
affected child’s genotype.
Finally, we assessed whether the maternal genotype
alone creates an adverse prenatal environment, by test-
ing the null hypothesis of no association between the
disease and the maternal genotype at or near the RHD
locus. For this analysis, we compared the model in
which , , and are estimated to a modelln (M) ln (S ) ln (S )1 2
in which is estimated and and areln (M) ln (S ) ln (S )1 2
constrained to their null value (0). This comparison pro-
duced no evidence to support that a maternal genotype
effect alone is associated with schizophrenia, as mea-
sured by association with a high-risk allele at or near
the RHD locus ( ; 2 df; [two-sided] ).2x p 0.56 Pp .76
Discussion
These results replicate previous findings that implicate
the RHD locus in schizophrenia, and the candidate-gene
design of the present study allows the elimination of
alternative explanations of the role of this locus in
schizophrenia. Thus, this study provides additional ev-
idence that the RHD locus increases schizophrenia risk
through a maternal-fetal genotype incompatibilitymech-
anism that increases risk of an adverse prenatal envi-
ronment rather than through linkage/association with
the disorder, through LD with an unknown nearby sus-
ceptibility locus, or through a direct maternal effect
alone. This is the first candidate-gene study to explicitly
test for and provide evidence of a maternal-fetal geno-
type incompatibility mechanism in schizophrenia.
The presence of an RHD maternal-fetal genotype in-
compatibility effect suggests that susceptibility to schizo-
phrenia may be increased by production of maternal anti-
D antibodies. This biological mechanism is consistent
with the teratogenic antibody hypothesis of interference
with normal fetal neurodevelopment (Laing et al. 1995).
Because the effects of an RHD maternal-fetal genotype
incompatibility occur during pregnancy, this biological
mechanism is also consistent with repeated findings that
obstetric complications occur more frequently among
births of individuals with schizophrenia (Marcelis et al.
1998; Cannon et al. 2000; Zornberg et al. 2000; Dalman
et al. 2001) and are associated with structural brain ab-
normalities in schizophrenia (McNeil et al. 2000).
The estimate of the incompatibility parameter in this
study (2.6) is consistent with an odds ratio of 2.0 (Can-
non et al. 2002), as well as with an estimate of the in-
compatibility parameter (1.8) that can be derived from
the data presented by Hollister et al. (1996) and an odds
ratio of 2.0 summarized in Hollister (2001). This con-
sistency is remarkable, given differences in study design
(population, case-control, and family-based studies) and
population cohort (United Kingdom/Scotland, Denmark,
and Finland). Such consistency across studies suggests
that our result is substantively significant and that the
statistical significance should be interpreted in light of
the moderate sample size. It also suggests that replication
studies should be designed to have sufficient power to
detect an effect size of ∼2.5. Using RHD genotype fre-
quencies as observed in the Finnish data collection, we
calculate that a sample of 130 patient-parent trios would
be needed to obtain 0.80 power to detect an incompat-
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ibility effect of this magnitude in a one-sided test with
.ap 0.05
The relative risk associated with RHD maternal-fetal
genotype incompatibility acting alone is computed by
multiplying the estimates of the incompatibility param-
eter ( ) and the parameter measuring the effectMp 2.6
of a single copy of the d allele in the affected child’s
genotype ( ), because both parameters contrib-R p .871
ute to the at-risk trio category. With a relative risk of
2.26, the risk of schizophrenia due to RHD maternal-
fetal genotype incompatibility acting alone is rather
small; and, in fact, many individuals who have an RHD
genotype incompatibility with their mother do not have
schizophrenia. However, because this relative risk rep-
resents an average, some individuals will be at higher risk
due to an RHD maternal-fetal genotype incompatibility,
and some individuals will be at lower risk. Previous re-
search has suggested that there is an association between
certain classes of obstetric complications (such as hypox-
ia) and familial risk for schizophrenia (Zornberg et al.
2000). Because Rh incompatibility can lead to fetal hy-
poxia, it is possible that anRHDmaternal-fetal genotype
incompatibility co-occurs with one or more susceptibility
genes elsewhere in the genome, to ultimately give rise to
the disorder. Stratifying samples by RHD maternal-fetal
genotype incompatibility may help to identify other
schizophrenia susceptibility genes.
There has been no indication from recent genome
scans that a schizophrenia susceptibility locus is located
in the region of chromosome 1p that contains the RHD
locus (Waterwort et al. 2002). However, this should not
be interpreted as lack of evidence for involvement of
the RHD locus in schizophrenia. Negative genome scan
results in that region are not surprising, given that those
statistical methods typically evaluate for the presence of
linkage or association between a high-risk allele and
disease and do not adequately model the maternal-fetal
genotype incompatibility mechanism. We demonstrated
that, even in the current sample, there is no evidence
for the direct effect of a high-risk allele at or near the
RHD locus, although there is evidence for RHD ma-
ternal-fetal genotype incompatibility. Thus, “negative”
genome scan results for the 1p region do not indicate
a failure to replicate our results, because such tests are
not sufficiently sensitive to the incompatibility mecha-
nism to reveal the role of RHD in schizophrenia (J.S.S.,
C.G.S.P., and J.A.W., unpublished data).
An assumption of the MFG test is that the probability
of an affected individual surviving to clinical detection
does not depend on the RHD genotypes of the mother,
father, and child (Umbach and Weinberg 2000). When
assessing prenatal risk factors, this assumption becomes
particularly relevant. In the case of the RHD locus, the
magnitude of fetal loss due to an incompatibility may
not be large enough to violate this assumption, because
most children survive the sequelae of Rh incompatibility
without prophylaxis (Guyton 1981; Chavez 1991).
Even if the assumption is violated, the effect of fetal
loss due to RHD maternal-fetal genotype incompati-
bility would be to reduce the number of observed in-
compatibilities in the patient-parent trios, thereby yield-
ing a conservative test that would be less likely to reject
the null hypothesis of no incompatibility.
The present study provides evidence for an RHD ma-
ternal-fetal genotype incompatibility effect in a sample
drawn from a population born before the widespread
use of prophylaxis. Even in the presence of prophylaxis,
there are several reasons why an RHD maternal-fetal
genotype incompatibility remains a risk factor for
schizophrenia. First, active production of maternal anti-
D antibodies still occurs in some at-risk pregnancies,
either because prophylaxis is not used (Chavez 1991;
Bowman 1998) or because its use is not 100% effective
at preventing maternal sensitization (de Silva et al.
1985; Thornton et al. 1989). Second, anti-D antibodies
produced through passive administration (i.e., prophy-
laxis) can cross the placenta and are measurable in fetal
antibody titres (Maayan-Metzger et al. 2001) and, thus,
may produce difficult-to-document transient hemolytic
effects that contribute to an increased risk for schizo-
phrenia. Future research is needed to determine the ex-
tent to which the availability of prophylaxis has reduced
the relative risk of schizophrenia due to RHD maternal-
fetal genotype incompatibility, before prophylaxis can
be viewed as playing an important role in the prevention
of some cases of schizophrenia.
Candidate-gene studies of schizophrenia typically
have focused on genes involved in neurochemical path-
ways (Jurewicz et al. 2001; Waterwort et al. 2002), and
the present study suggests that genes that relate to im-
munological pathways could also be involved in the
development of this neuropsychiatric disease. One such
immunological pathway produces fetal hypoxia and hy-
perbilirubinemia; therefore, other genes that could pro-
duce one or both of these conditions when present as
maternal-fetal genotype incompatibilities (e.g., ABO
[MIM 110300]) or when present simply as high-risk
alleles in the child’s genotype (e.g., FV Leiden mutation
[MIM 227400.0001]) should be investigated as candi-
date genes for schizophrenia. Another potential im-
munological pathway is the intolerance that results from
maternal-fetal human leukocyte antigen similarity,
whereby the mother fails to stimulate blocking anti-
bodies that normally protect the fetus from the mother’s
immune response (Stubbs et al. 1985; Van Gent et al.
1997; Ober 1998). Research directed at elucidating the
effect that an RHD maternal-fetal genotype incompat-
ibility has on fetal neurodevelopment may identify an
important pathway in the development of schizophrenia
1318 Am. J. Hum. Genet. 71:1312–1319, 2002
and could shed light on other risk factors that share the
same pathway.
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